2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
Ulf Landmesser,M. John Chapman,Jane K Stock,Pierre Amarenco,Jill J. F. Belch,Jan Borén,Michel Farnier,Brian A. Ference,Stephan Gielen,Ian D. Graham,Diederick E. Grobbee,G. Kees Hovingh,Thomas F. Lüscher,Massimo F Piepoli,Kausik K. Ray,Erik S.G. Stroes,Olov Wiklund,Stephan Windecker,José Luis Zamorano,Fausto J. Pinto,Lale Tokgozoglu,Jeroen J. Bax,Alberico L. Catapano +22 more
Reads0
Chats0
TLDR
A correction has been published: European Heart Journal, Volume 39, Issue 22, 7 June 2018, pages 2105 and 2105.Abstract:
A correction has been published: European Heart Journal, Volume 39, Issue 22, 7 June 2018, Pages 2105read more
Citations
More filters
Journal ArticleDOI
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
Marc S. Sabatine,Gaetano M. De Ferrari,Robert P. Giugliano,Kurt Huber,Basil S. Lewis,Jorge Ferreira,Julia F Kuder,Sabina A. Murphy,Stephen D. Wiviott,Christopher E. Kurtz,Narimon Honarpour,Anthony C Keech,Peter S. Sever,Terje R. Pedersen +13 more
TL;DR: Patients closer to their most recent MI, with multiple prior MIs, or with residual multivessel coronary artery disease are at high risk for major vascular events and experience substantial risk reductions with low-density lipoprotein cholesterol lowering with evolocumab.
Journal ArticleDOI
Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association
Suzanne V. Arnold,Deepak L. Bhatt,Gregory W. Barsness,Alexis L. Beatty,Prakash Deedwania,Silvio E. Inzucchi,Mikhail Kosiborod,Lawrence A. Leiter,Kasia J. Lipska,Jonathan D. Newman,Francine K. Welty +10 more
TL;DR: The role that T2DM has in the selection of testing for CAD, in medical management (both secondary prevention strategies and treatment of stable angina), and in theselection of revascularization strategy are discussed.
Journal ArticleDOI
Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis
TL;DR: Low-density lipoprotein cholesterol lowering was not associated with an increased risk of serious adverse events, myalgias and/or myositis, elevation in the level of aminotransferases, new-onset diabetes, hemorrhagic stroke, or cancer.
Journal ArticleDOI
2018 Guidelines for the management of dyslipidemia
Eun-Jung Rhee,Hyeon Chang Kim,Jae Hyeon Kim,Eun Young Lee,Byung Jin Kim,Eun Mi Kim,YoonJu Song,Jeong Hyun Lim,Hae Jin Kim,Seonghoon Choi,Min Kyong Moon,Jin Oh Na,Kwang-Yeol Park,Mi Sun Oh,Sang Youb Han,Jung Hyun Noh,Kyung Hee Yi,Sang Hak Lee,Soon Cheol Hong,In Kyung Jeong +19 more
TL;DR: The fourth guidelines for the treatment of dyslipidemia specific to Koreans are developed based on evidence and expert opinions on the dynamically changing treatment modalities for dys Lipididemia.
Journal ArticleDOI
HIV infection and coronary heart disease: mechanisms and management.
TL;DR: The epidemiology and clinical features of cardiovascular disease in patients with HIV infection are discussed, including the mechanisms underlying HIV-associated atherosclerosis and approaches to reduce the cardiovascular risk.
References
More filters
Journal ArticleDOI
2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
Giuseppe Mancia,Robert Fagard,Krzysztof Narkiewicz,Josep Redon,Alberto Zanchetti,Michael Böhm,Thierry Christiaens,Renata Cifkova,Guy De Backer,Anna F. Dominiczak,Maurizio Galderisi,Diederick E. Grobbee,Tiny Jaarsma,Paulus Kirchhof,Sverre E. Kjeldsen,Stéphane Laurent,Athanasios J. Manolis,Peter M. Nilsson,Luis M. Ruilope,Roland E. Schmieder,Per Anton Sirnes,Peter Sleight,Margus Viigimaa,Bernard Waeber,Faiez Zannad,Michel Burnier,Ettore Ambrosioni,Mark Caufield,Antonio Coca,Michael H. Olsen,Costas Tsioufis,Philippe van de Borne,José Luis Zamorano,Stephan Achenbach,Helmut Baumgartner,Jeroen J. Bax,Héctor Bueno,Veronica Dean,Christi Deaton,Çetin Erol,Roberto Ferrari,David Hasdai,Arno W. Hoes,Juhani Knuuti,Philippe Kolh,Patrizio Lancellotti,Aleš Linhart,Petros Nihoyannopoulos,Massimo F Piepoli,Piotr Ponikowski,Juan Tamargo,Michal Tendera,Adam Torbicki,William Wijns,Stephan Windecker,Denis Clement,Thierry C. Gillebert,Enrico Agabiti Rosei,Stefan D. Anker,Johann Bauersachs,Jana Brguljan Hitij,Mark J. Caulfield,Marc De Buyzere,Sabina De Geest,Geneviève Derumeaux,Serap Erdine,Csaba Farsang,Christian Funck-Brentano,Vjekoslav Gerc,Giuseppe Germanò,Stephan Gielen,Herman Haller,Jens Jordan,Thomas Kahan,Michel Komajda,Dragan Lovic,Heiko Mahrholdt,Jan Östergren,Gianfranco Parati,Joep Perk,Jorge Polónia,Bogdan A. Popescu,Zeljko Reiner,Lars Rydén,Yuriy Sirenko,Alice Stanton,Harry A.J. Struijker-Boudier,Charalambos Vlachopoulos,Massimo Volpe,David A. Wood +89 more
TL;DR: In this article, a randomized controlled trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly people was presented. But the authors did not discuss the effect of the combination therapy in patients living with systolic hypertension.
Journal Article
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Anders G. Olsson,Jjv McMurray,Gudmundur Thorgeirsson,C Spaulding,J Slattery,Kalevi Pyörälä,Ole Faergeman,RA Wright,Kåre Berg,Lars Wilhelmsen,Terje R. Pedersen,Tatu A. Miettinen,Harvey D. White,John Kjekshus,Michael Gnant +14 more
Journal ArticleDOI
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)
Massimo Piepoli,Arno W. Hoes,Stefan Agewall,Christian Albus,Carlos Brotons,Alberico L. Catapano,Marie Therese Cooney,Ugo Corrà,Bernard Cosyns,Christi Deaton,Ian D. Graham,Michael Stephen Hall,FD Richard Hobbs,Maja Lisa Løchen,Herbert Löllgen,Pedro Marques-Vidal,Joep Perk,Eva Prescott,Josep Redon,Dimitrios J. Richter,Naveed Sattar,Y.M. Smulders,Monica Tiberi,H. Bart van der Worp,Ineke van Dis,W M Monique Verschuren +25 more
TL;DR: In this paper, a randomized clinical trial was conducted to evaluate the effect of preterax and Diamicron Modified Release Controlled Evaluation (MDE) on the risk of stroke.
Journal ArticleDOI
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo Piepoli,Arno W. Hoes,Stefan Agewall,Christian Albus,Carlos Brotons,Alberico L. Catapano,Marie Therese Cooney,Ugo Corrà,Bernard Cosyns,Christi Deaton,Ian D. Graham,Michael Stephen Hall,FD Richard Hobbs,Maja-Lisa Løchen,Herbert Löllgen,Pedro Marques-Vidal,Joep Perk,Eva Prescott,Josep Redon,Dimitrios J. Richter,Naveed Sattar,Yvo M. Smulders,Monica Tiberi,H. Bart van der Worp,Ineke van Dis,W. M. Monique Verschuren +25 more
TL;DR: ABI is ankle-brachial (blood pressure) index and ABPM is ambulatory blood pressure monitoring as mentioned in this paper ; ACCORD is action to control cardiovascular risk in Diabetes and Vascular disease.
Journal ArticleDOI
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine,Robert P. Giugliano,Anthony C Keech,Narimon Honarpour,Stephen D. Wiviott,Sabina A. Murphy,Sabina A. Murphy,Julia F Kuder,Julia F Kuder,Huei Wang,Thomas Liu,Scott M. Wasserman,Peter S. Sever,Terje R. Pedersen,Terje R. Pedersen +14 more
TL;DR: In this trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events.
Related Papers (5)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano,Ian D. Graham,Guy De Backer,Olov Wiklund,M. John Chapman,Heinz Drexel,Arno W. Hoes,Catriona Jennings,Ulf Landmesser,Terje R. Pedersen,Željko Reiner,Gabriele Riccardi,Marja-Riitta Taskinen,Lale Tokgozoglu,W. M. Monique Verschuren,Charalambos Vlachopoulos,David R. Wood,José Luis Zamorano +17 more
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference,Henry N. Ginsberg,Ian D. Graham,Kausik K. Ray,Chris J. Packard,Eric Bruckert,Robert A. Hegele,Ronald M. Krauss,Frederick J. Raal,Heribert Schunkert,Gerald F. Watts,Jan Borén,Sergio Fazio,Jay D. Horton,Luis Masana,Stephen J. Nicholls,Børge G. Nordestgaard,Børge G. Nordestgaard,Bart van de Sluis,Marja-Riitta Taskinen,Lale Tokgozoglu,Ulf Landmesser,Ulf Landmesser,Ulf Landmesser,Ulrich Laufs,Olov Wiklund,Olov Wiklund,Jane K Stock,M. John Chapman,Alberico L. Catapano +29 more